Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$635K Sell
5,607
-1,146
-17% -$126K 0.06% 380
2022
Q3
$543K Sell
6,753
-367
-5% -$31.1K 0.07% 403
2022
Q2
$530K Sell
7,120
-3,596
-34% -$328K 0.06% 443
2022
Q1
$1.37M Sell
10,716
-1,900
-15% -$208K 0.14% 266
2021
Q4
$1.69M Sell
12,616
-2,128
-14% -$306K 0.16% 211
2021
Q3
$2.02M Buy
14,744
+2,004
+16% +$253K 0.19% 159
2021
Q2
$1.36M Buy
12,740
+56
+0.4% +$5.38K 0.13% 254
2021
Q1
$1.14M Sell
12,684
-5,020
-28% -$471K 0.11% 280
2020
Q4
$1.64M Buy
17,704
+4,444
+34% +$397K 0.17% 203
2020
Q3
$1.37M Buy
13,260
+352
+3% +$36.8K 0.15% 212
2020
Q2
$1.31M Sell
12,908
-200
-2% -$17.9K 0.15% 209
2020
Q1
$739K Buy
13,108
+9,996
+321% +$622K 0.1% 288
2019
Q4
$170K Hold
3,112
0.02% 564
2019
Q3
$116K Hold
3,112
0.01% 571
2019
Q2
$117K Sell
3,112
-15,480
-83% -$487K 0.01% 595
2019
Q1
$554K Buy
+18,592
New +$653K 0.05% 448

Other funds holding DXCM

Seeyond's DXCM Position: Q4 2022 in Review

Seeyond reduced its DexCom (DXCM) stake by 17% in Q4 2022, selling an estimated $126K and leaving 5,607 shares worth $635K. The position accounts for 0.06% of the portfolio, ranked #380.

Seeyond first reported a position in DXCM in Q1 2019 and has held it in 16 quarters since. The position peaked at $2.02M in Q3 2021. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2022.

  • Seeyond held 5,607 shares of DexCom worth $635K as of Q4 2022.
  • Seeyond sold 1,146 DexCom shares in Q4 2022, an estimated $126K.
  • DexCom made up 0.06% of Seeyond's portfolio in Q4 2022, its #380 holding.
  • Seeyond first reported a position in DexCom in Q1 2019 and has held it in 16 quarters since.
  • Seeyond's DexCom position peaked at $2.02M in Q3 2021.
  • 920 funds tracked by Wall St. Rank held DexCom as of Q4 2022.

Based on Seeyond's 13F filing for Q4 2022, filed 13 Feb 2023.